Tyverb still not cost-effective for breast cancer, says NICE
This article was originally published in Scrip
Executive Summary
NICE, the UK's National Institute for health and Clinical Excellence, maintains that GlaxoSmithKline's Tyverb (lapatinib) is not cost-effective and should not be used to treat previously treated women with advanced or metastatic breast cancer on the NHS in England and Wales.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.